Stryker Co. (NYSE:SYK) Stock Holdings Lifted by Sivik Global Healthcare LLC

Sivik Global Healthcare LLC lifted its holdings in Stryker Co. (NYSE:SYK - Free Report) by 8.0% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 27,000 shares of the medical technology company's stock after buying an additional 2,000 shares during the period. Stryker comprises 4.1% of Sivik Global Healthcare LLC's holdings, making the stock its 7th largest holding. Sivik Global Healthcare LLC's holdings in Stryker were worth $9,754,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. International Assets Investment Management LLC boosted its position in Stryker by 66,967.5% in the 3rd quarter. International Assets Investment Management LLC now owns 853,769 shares of the medical technology company's stock worth $308,433,000 after purchasing an additional 852,496 shares in the last quarter. JPMorgan Chase & Co. raised its position in shares of Stryker by 10.4% in the first quarter. JPMorgan Chase & Co. now owns 8,651,403 shares of the medical technology company's stock valued at $3,096,078,000 after buying an additional 813,311 shares during the last quarter. 1832 Asset Management L.P. raised its holdings in Stryker by 146.9% in the 1st quarter. 1832 Asset Management L.P. now owns 878,669 shares of the medical technology company's stock valued at $314,449,000 after acquiring an additional 522,817 shares during the last quarter. American Century Companies Inc. increased its holdings in shares of Stryker by 287.6% in the second quarter. American Century Companies Inc. now owns 505,608 shares of the medical technology company's stock valued at $172,033,000 after purchasing an additional 375,166 shares during the last quarter. Finally, Vanguard Group Inc. raised its holdings in shares of Stryker by 1.0% during the 1st quarter. Vanguard Group Inc. now owns 31,459,393 shares of the medical technology company's stock worth $11,258,373,000 after acquiring an additional 309,592 shares during the period. 77.09% of the stock is currently owned by hedge funds and other institutional investors.

Stryker Stock Performance

Shares of Stryker stock traded down $5.06 on Thursday, reaching $383.28. 1,763,435 shares of the stock were exchanged, compared to its average volume of 1,259,397. The company has a current ratio of 1.91, a quick ratio of 1.22 and a debt-to-equity ratio of 0.66. The business has a fifty day moving average price of $362.94 and a two-hundred day moving average price of $346.72. The firm has a market capitalization of $146.11 billion, a PE ratio of 41.62, a PEG ratio of 2.92 and a beta of 0.91. Stryker Co. has a 1-year low of $282.35 and a 1-year high of $392.70.

Stryker (NYSE:SYK - Get Free Report) last released its quarterly earnings data on Tuesday, October 29th. The medical technology company reported $2.87 EPS for the quarter, topping analysts' consensus estimates of $2.77 by $0.10. Stryker had a net margin of 16.34% and a return on equity of 23.07%. The firm had revenue of $5.49 billion for the quarter, compared to the consensus estimate of $5.37 billion. During the same quarter in the previous year, the firm earned $2.46 earnings per share. The firm's revenue was up 11.9% on a year-over-year basis. As a group, research analysts anticipate that Stryker Co. will post 12.06 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research analysts recently commented on the company. Canaccord Genuity Group upped their price objective on Stryker from $360.00 to $400.00 and gave the company a "buy" rating in a report on Wednesday, October 30th. Truist Financial lifted their price objective on shares of Stryker from $370.00 to $380.00 and gave the company a "hold" rating in a report on Wednesday, October 30th. Stifel Nicolaus cut their price target on Stryker from $375.00 to $365.00 and set a "buy" rating on the stock in a report on Wednesday, July 31st. Wolfe Research started coverage on shares of Stryker in a research report on Tuesday, September 10th. They set an "outperform" rating and a $405.00 price objective for the company. Finally, Royal Bank of Canada boosted their target price on Stryker from $386.00 to $400.00 and gave the stock an "outperform" rating in a research note on Wednesday, October 30th. Four analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $393.65.

Insider Transactions at Stryker

In related news, CEO Kevin Lobo sold 57,313 shares of the business's stock in a transaction dated Thursday, November 7th. The shares were sold at an average price of $368.70, for a total transaction of $21,131,303.10. Following the completion of the sale, the chief executive officer now owns 100,027 shares of the company's stock, valued at $36,879,954.90. This represents a 36.43 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP M Kathryn Fink sold 7,347 shares of Stryker stock in a transaction dated Tuesday, September 17th. The shares were sold at an average price of $366.98, for a total transaction of $2,696,202.06. Following the completion of the sale, the vice president now owns 10,042 shares in the company, valued at approximately $3,685,213.16. This represents a 42.25 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 67,381 shares of company stock valued at $24,825,275 in the last 90 days. 5.90% of the stock is currently owned by insiders.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.